{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:33Z","timestamp":1789001253842,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774279"],"award-info":[{"award-number":["81774279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and objective:<\/jats:bold> Pruritus is a common complication in patients with primary biliary cholangitis (PBC). The pathogenesis is not clear, and also the precise therapeutic measures remain alluring. In order to systematically evaluate the efficacy and safety of drug interventions in the treatment of pruritus associated with PBC, this systemic review and meta-analysis was conducted.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The randomized controlled trials (RCTs) on drug interventions in the treatment of pruritus associated with primary cholangitis were searched in the electronic databases of PubMed, EMBASE, Cochrane Library, Web of Science, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>. Two researchers independently screened the literature, extracted and integrated the data, and assessed the bias risk of the selected literature, according to the <jats:italic>Cochrane handbook<\/jats:italic>. Finally, the STATA 15.0 software was used for the meta-analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 23 RCTs involving 2,194 patients were studied, that included 12 pharmacological interventions. In terms of itching relief, compared with placebo, UDCA, methotrexate and GSK2330672 had a definite effect in improving pruritus (pruritus remission rate before and after treatment, <jats:italic>p &amp;lt;<\/jats:italic> 0.05). In terms of serum indexes, compared with placebo group, UDCA, OCA, rifampicin, cyclosporine, NGM282, seladelpar and colchicine may improve blood alkaline phosphatase (ALP) (<jats:italic>p &amp;lt;<\/jats:italic> 0.05), but only rifampicin showed low heterogeneity. UDCA, bezafibrate, OCA, rifampicin, NGM282 and others may improve blood \u03b3-glutamyl transpeptidase (\u03b3-GGT) (<jats:italic>p &amp;lt;<\/jats:italic> 0.05), but due to the high heterogeneity and the limitation of research samples, a clear conclusion cannot be drawn. In terms of adverse events, except high (&amp;gt;15\u00a0mg\/kg\/day) and low doses (&amp;lt;13\u00a0mg\/kg\/day) of UDCA increased the incidence of adverse events, there were no risk of increasing the incidence of adverse events compared with placebo (<jats:italic>p &amp;gt;<\/jats:italic> 0.05), and a moderate dose of UDCA (13\u201315\u00a0mg\/kg\/day) and malotilate (1,500\u00a0mg\/day) may also help in reducing the incidence of adverse events (<jats:italic>p &amp;lt;<\/jats:italic> 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> UDCA, methotrexate and GSK2330672 may relieve itching in patients with PBC, but there is a lack of robust evidence to support their effect on ALP or \u03b3-GGT. Due to the heterogeneity in the published studies, based on the present review, we cannot explicitly recommend any specific drug for the treatment of PBC-related pruritus.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>link-https:\/\/osf.io\/2g8ya<\/jats:ext-link>, identifier 10.17605\/OSF.IO\/2G8YA<\/jats:p>","DOI":"10.3389\/fphar.2022.835991","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:45:41Z","timestamp":1666262741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chenyi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1046\/j.1365-2036.2000.00869.x","article-title":"Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis","volume":"14","author":"Almasio","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/s0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0168-8278(05)80214-4","article-title":"Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC","volume":"17","author":"Battezzati","year":"1993","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: Facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1210\/er.2017-00253","article-title":"The science of obesity management: An endocrine society scientific statement","volume":"39","author":"Bray","year":"2018","journal-title":"Endocr. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/s0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Cn","year":"1988","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"adv00653","DOI":"10.2340\/actadv.v102.310","article-title":"Efficacy of treatments for cholestatic pruritus: A systemic review and meta-analysis","volume":"102","author":"Dervout","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Dg","year":"2009","journal-title":"BMJ Clin. Res. ed.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00038-020-01391-6","article-title":"Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia","volume":"65","author":"Drazilova","year":"2020","journal-title":"Int. J. Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Gideon","year":"2017","journal-title":"J. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD005526","DOI":"10.1002\/14651858.CD005526.pub2","article-title":"Cyclosporin A for primary biliary cirrhosis","volume":"3","author":"Gong","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD004385","DOI":"10.1002\/14651858.CD004385.pub2","article-title":"Methotrexate for primary biliary cirrhosis","volume":"3","author":"Gong","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"CD000551","DOI":"10.1002\/14651858.CD000551.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"3","author":"Gong","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: Pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.2147\/DDDT.S79837","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: A meta-analysis","volume":"9","author":"Guo","year":"2015","journal-title":"Drug Des. devel. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0270-9139(95)90074-8","article-title":"The Canadian multi-center double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1995","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: A double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low-dose methotrexate is ineffective in primary biliary cirrhosis: Long-term results of a placebo-controlled trial","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"B24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.1038\/s41598-019-47890-2","article-title":"Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort","volume":"9","author":"Hu","year":"2019","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jgh.14924","article-title":"Increasing prevalence of primary biliary cholangitis in Victoria, Australia","volume":"35","author":"J","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"CD000551","DOI":"10.1002\/14651858.CD000551.pub3","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Js","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02430.x","article-title":"A controlled trial of ondansetron in the pruritus of cholestasis","volume":"21","author":"Jw","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: A new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Kd","year":"2019","journal-title":"Hepatol. Baltim. Md.)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s10620-019-5457-5","article-title":"Treatment of fatigue in primary biliary cholangitis: A systematic review and meta-analysis","volume":"64","author":"Lee","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0168-8278(05)80043-1","article-title":"The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group","volume":"17","author":"Listed","year":"1993","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mj","year":"2007","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/BF02779195","article-title":"A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis","volume":"25","author":"Oka","year":"1991","journal-title":"Gastroenterol. Jpn."},{"key":"B41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-cooperative group from the Spanish association for the study of the liver","volume":"32","author":"Par\u00e9s","year":"2000","journal-title":"J. Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig. Dis. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0168-8278(90)90265-s","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: Interim analysis of a double-blind multicentre randomized trial","volume":"11","author":"Poupon","year":"1990","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis","volume":"35","author":"Quarneti","year":"2015","journal-title":"Liver Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/1753-0407.12839","article-title":"Population attributable fractions of the main type 2 diabetes mellitus risk factors in women: Findings from the French E3N cohort","volume":"11","author":"Rajaobelina","year":"2019","journal-title":"J. Diabetes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jaad.2019.04.035","article-title":"Cholestatic pruritus: Emerging mechanisms and therapeutics","volume":"81","author":"Sp","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","article-title":"Recent advances in the management of pruritus in chronic liver diseases","volume":"23","author":"Tajiri","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/nejm196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine","volume":"265","author":"Tb","year":"1961","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the asia\u2013pacific region: A systematic review and meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Hepatol. Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/hepr.12373","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis","volume":"45","author":"Zhang","year":"2015","journal-title":"Hepatol. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.835991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:45:56Z","timestamp":1666262756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.835991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":56,"alternative-id":["10.3389\/fphar.2022.835991"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.835991","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"835991"}}